相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Update of the International Consultation on Urological Diseases on bladder cancer 2018: non-urothelial cancers of the urinary bladder
Shaheen Alanee et al.
WORLD JOURNAL OF UROLOGY (2019)
Molecular profiling in muscle-invasive bladder cancer: more than the sum of its parts
Gottfrid Sjodahl et al.
JOURNAL OF PATHOLOGY (2019)
The Impact of Plasmacytoid Variant Histology on the Survival of Patients with Urothelial Carcinoma of Bladder after Radical Cystectomy
Qiang Li et al.
EUROPEAN UROLOGY FOCUS (2019)
Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy
Kenneth M. Felsenstein et al.
NATURE REVIEWS UROLOGY (2018)
Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab
Shuguang Tan et al.
PROTEIN & CELL (2018)
Cancer Statistics, 2018
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
New 6-factor prognostic model for patients (pts) with advanced urothelial carcinoma (UC) receiving post-platinum atezolizumab.
Gregory Russell Pond et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Erdafitinib (ERDA; JNJ-42756493), a pan-fibroblast growth factor receptor (FGFR) inhibitor, in patients (pts) with metastatic or unresectable urothelial carcinoma (mUC) and FGFR alterations (FGFRa): Phase 2 continuous versus intermittent dosing.
Yohann Loriot et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers
Min Yuen Teo et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel et al.
LANCET ONCOLOGY (2018)
A practical guide to bladder cancer pathology
Eva Comperat et al.
NATURE REVIEWS UROLOGY (2018)
Biomarker challenges for immune checkpoint inhibitors in urothelial carcinoma
Tom Powles et al.
NATURE REVIEWS UROLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Clinical characteristics and outcomes of nonurothelial cell carcinoma of the bladder: Results from the National Cancer Data Base
Trevor J. Royce et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2018)
Loss of functional BAP1 augments sensitivity to TRAIL in cancer cells
Krishna Kalyan Kolluri et al.
ELIFE (2018)
Immune checkpoint inhibitors in small cell lung cancer
Suchita Pakkala et al.
JOURNAL OF THORACIC DISEASE (2018)
Atezolizumab (MPDL3280A) Monotherapy for Patients With Metastatic Urothelial Cancer Long-term Outcomes From a Phase 1 Study
Daniel P. Petrylak et al.
JAMA ONCOLOGY (2018)
Safety and activity of M7824, a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients with HPV associated cancers.
Julius Strauss et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
EV-201 Study: A single-arm, open-label, multicenter study of enfortumab vedotin for treatment of patients with locally advanced or metastatic urothelial cancer who previously received immune checkpoint inhibitor therapy.
Jonathan E. Rosenberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment
Yien Ning Sophia Wong et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2018)
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Sanjeev Mariathasan et al.
NATURE (2018)
EMA and FDA prune the checkpoint inhibitor treatment landscape
Min Yuen Teo et al.
NATURE REVIEWS UROLOGY (2018)
Downstaging and Survival Outcomes Associated With Neoadjuvant Chemotherapy Regimens Among Patients Treated With Cystectomy for Muscle-Invasive Bladder Cancer
Charles C. Peyton et al.
JAMA ONCOLOGY (2018)
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study
Andrea Necchi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Clear Cell Urothelial Carcinoma: A Study of 10 Cases and Meta-Analysis of the Entity. Evidence of Mesonephric Differentiation
Kien T. Mai et al.
INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY (2017)
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
Roland Seiler et al.
EUROPEAN UROLOGY (2017)
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset
Woonyoung Choi et al.
EUROPEAN UROLOGY (2017)
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Lucia Nogova et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Targeted DNA and RNA sequencing of paired urothelial and squamous bladder cancers to reveal discordant genomic and transcriptomic events and unique therapeutic opportunities.
Daniel H. Hovelson et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Avelumab, an Anti-Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
Andrea B. Apolo et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial
Daniel P. Petrylak et al.
LANCET (2017)
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
Arjun V. Balar et al.
LANCET (2017)
Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial
Beatrice Seddon et al.
LANCET ONCOLOGY (2017)
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V. Balar et al.
LANCET ONCOLOGY (2017)
Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study
Elizabeth R. Plimack et al.
LANCET ONCOLOGY (2017)
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2017)
Next-generation sequencing-based molecular characterization of primary urinary bladder adenocarcinoma
Somak Roy et al.
MODERN PATHOLOGY (2017)
Characteristics and clinical significance of histological variants of bladder cancer
Marco Moschini et al.
NATURE REVIEWS UROLOGY (2017)
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
J. Bellmunt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab
Petros Fessas et al.
SEMINARS IN ONCOLOGY (2017)
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma Updated Results From a Phase 1/2 Open-label Study
Thomas Powles et al.
JAMA ONCOLOGY (2017)
Circulating Tumor DNA Reveals Clinically Actionable Somatic Genome of Metastatic Bladder Cancer
Gillian Vandekerkhove et al.
CLINICAL CANCER RESEARCH (2017)
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
A. Gordon Robertson et al.
CELL (2017)
A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)
J. Bellmunt et al.
ANNALS OF ONCOLOGY (2017)
Efficacy and Safety of Gemcitabine Plus Either Taxane or Carboplatin in the First-Line Setting of Metastatic Urothelial Carcinoma: A Systematic Review and Meta-Analysis
Andrea Necchi et al.
CLINICAL GENITOURINARY CANCER (2017)
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
G. Paolo Dotto et al.
CANCER CELL (2016)
Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models
Pia M. Challita-Eid et al.
CANCER RESEARCH (2016)
Genomic complexity of urothelial bladder cancer revealed in urinary cfDNA
Fiona S. Togneri et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2016)
Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer
Charles Chuanhai Guo et al.
EUROPEAN UROLOGY (2016)
Urachal Carcinoma Shares Genomic Alterations with Colorectal Carcinoma and May Respond to Epidermal Growth Factor Inhibition
Ana Collazo-Lorduy et al.
EUROPEAN UROLOGY (2016)
The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs-Part B: Prostate and Bladder Tumours
Peter A. Humphrey et al.
EUROPEAN UROLOGY (2016)
Primary sarcoma and sarcomatoid carcinoma of the urinary bladder: Comparison of clinical features, treatment, and survival
Jue Wang
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
Christophe Massard et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial
Padmanee Sharma et al.
LANCET ONCOLOGY (2016)
Synthetic Lethal Targeting of ARID1A-Mutant Ovarian Clear Cell Tumors with Dasatinib
Rowan E. Miller et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Mechanisms and regulation of endothelial VEGF receptor signalling
Michael Simons et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2016)
Clinical, prognostic, and therapeutic aspects of urachal carcinoma-A comprehensive review with meta-analysis of 1,010 cases
Tibor Szarvas et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2016)
Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use
Vipulkumar Dadhania et al.
EBIOMEDICINE (2016)
Micropapillary Bladder Cancer: Insights from the National Cancer Database
Wilson Sui et al.
BLADDER CANCER (2016)
Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting
Seth P. Lerner et al.
BLADDER CANCER (2016)
Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy
Andrea Necchi et al.
CLINICAL GENITOURINARY CANCER (2015)
Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer
Elizabeth R. Plimack et al.
EUROPEAN UROLOGY (2015)
Nonurothelial Bladder Cancer and Rare Variant Histologies
Daniel Willis et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2015)
An APOBEC3A hypermutation signature is distinguishable from the signature of background mutagenesis by APOBEC3B in human cancers
Kin Chan et al.
NATURE GENETICS (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Update for the practicing pathologist: The International Consultation On Urologic Disease-European association of urology consultation on bladder cancer
Mahul B. Amin et al.
MODERN PATHOLOGY (2015)
Pan-cancer network analysis identifies combinations of rare somatic mutations across pathways and protein complexes
Mark D. M. Leiserson et al.
NATURE GENETICS (2015)
A nomogram including baseline prognostic factors to estimate the activity of second-line therapy for advanced urothelial carcinoma
Gregory R. Pond et al.
BJU INTERNATIONAL (2014)
Identification of Distinct Basal and Luminal Subtypes of Muscle-Invasive Bladder Cancer with Different Sensitivities to Frontline Chemotherapy
Woonyoung Choi et al.
CANCER CELL (2014)
Phase 2 trial of dovitinib in patients with progressive FGFR3-mutated or FGFR3 wild-type advanced urothelial carcinoma
Matthew I. Milowsky et al.
EUROPEAN JOURNAL OF CANCER (2014)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
Comprehensive molecular characterization of urothelial bladder carcinoma
John N. Weinstein et al.
NATURE (2014)
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Thomas Powles et al.
NATURE (2014)
Systemic treatment of soft-tissue sarcoma -gold standard and novel therapies
Mark Linch et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2014)
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Alexandra Snyder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Jeffrey S. Damrauer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Plasmacytoid Bladder Cancer: Variant Histology With Aggressive Behavior and a New Mode of Invasion Along Fascial Planes
Hristos Z. Kaimakliotis et al.
UROLOGY (2014)
Independent Component Analysis Uncovers the Landscape of the Bladder Tumor Transcriptome and Reveals Insights into Luminal and Basal Subtypes
Anne Biton et al.
CELL REPORTS (2014)
Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC).
Thomas Powles et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Toward a Molecular Pathologic Classification of Urothelial Carcinoma
Gottfrid Sjodahl et al.
AMERICAN JOURNAL OF PATHOLOGY (2013)
Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer
Joshua J. Meeks et al.
BJU INTERNATIONAL (2013)
Phase II study of everolimus in metastatic urothelial cancer
Matthew I. Milowsky et al.
BJU INTERNATIONAL (2013)
Genomics-Driven Oncology: Framework for an Emerging Paradigm
Levi A. Garraway
JOURNAL OF CLINICAL ONCOLOGY (2013)
Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
Nienke van Rooij et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Gopa Iyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Plasmacytoid Urothelial Carcinoma, a Chemosensitive Cancer with Poor Prognosis, and Peritoneal Carcinomatosis
Farshid Dayyani et al.
JOURNAL OF UROLOGY (2013)
Signatures of mutational processes in human cancer
Ludmil B. Alexandrov et al.
NATURE (2013)
An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers
Steven A. Roberts et al.
NATURE GENETICS (2013)
Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells
Paul F. Robbins et al.
NATURE MEDICINE (2013)
Fibroblast growth factor receptor-3 in urothelial tumorigenesis
Gopa Iyer et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2013)
Survival after radical cystectomy of non-bilharzial squamous cell carcinoma vs urothelial carcinoma: a competing-risks analysis
Firas Abdollah et al.
BJU INTERNATIONAL (2012)
Pathologic Downstaging Is a Surrogate Marker for Efficacy and Increased Survival Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle-Invasive Urothelial Bladder Cancer
Robert Rosenblatt et al.
EUROPEAN UROLOGY (2012)
Randomized Phase III Study Comparing Paclitaxel/Cisplatin/Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Targeting the TGFβ signalling pathway in disease
Rosemary J. Akhurst et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Urachal Adenocarcinoma: A Clinician's Guide for Treatment
Arlene Siefker-Radtke
SEMINARS IN ONCOLOGY (2012)
A Surveillance, Epidemiology, and End Results analysis of small cell carcinoma of the bladder
Eugene J. Koay et al.
CANCER (2011)
Plasmacytoid urothelial carcinoma of the urinary bladder: clinicopathologic, immunohistochemical, ultrastructural, and molecular analysis of a case series
Maria Rosaria Raspollini et al.
HUMAN PATHOLOGY (2011)
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
Caroline Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer (vol 17, pg v118, 2006)
Hans von der Maase et al.
ANNALS OF ONCOLOGY (2011)
Phase II Evaluation of Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study
Matthew A. Powell et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers
R. S. van der Post et al.
JOURNAL OF MEDICAL GENETICS (2010)
Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium
Guru Sonpavde et al.
LANCET ONCOLOGY (2010)
Micropapillary urothelial carcinoma of the urinary bladder: a clinicopathological analysis of 72 cases
Eva Comperat et al.
PATHOLOGY (2010)
Adenocarcinoma Versus Urothelial Carcinoma of the Urinary Bladder: Comparison Between Pathologic Stage at Radical Cystectomy and Cancer-specific Mortality
Giovanni Lughezzani et al.
UROLOGY (2010)
Fibroblast growth factor signalling: from development to cancer
Nicholas Turner et al.
NATURE REVIEWS CANCER (2010)
Urachal Carcinoma A Clinicopathologic Analysis of 24 Cases With Outcome Correlation
Anuradha Gopalan et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2009)
A Single-arm, Multicenter, Open-label Phase 2 Study of Lapatinib as the Second-line Treatment of Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma
Christian Wuelfing et al.
CANCER (2009)
Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer
Jose J. Mansure et al.
CANCER BIOLOGY & THERAPY (2009)
FGFR3 Mutations Indicate Better Survival in Invasive Upper Urinary Tract and Bladder Tumours
Johanna M. M. van Oers et al.
EUROPEAN UROLOGY (2009)
Randomized Phase II/III Trial Assessing Gemcitabine/Carboplatin and Methotrexate/Carboplatin/Vinblastine in Patients With Advanced Urothelial Cancer Unfit for Cisplatin-Based Chemotherapy: Phase II-Results of EORTC Study 30986
Maria De Santis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract
Joaquim Bellmunt et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
Robert J. Motzer et al.
LANCET (2008)
Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
Jorge A. Garcia et al.
MOLECULAR CANCER THERAPEUTICS (2008)
Cancer-related inflammation
Alberto Mantovani et al.
NATURE (2008)
Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder - A contemporary review of the University of Texas M.D. Anderson Cancer Center experience
Wassim Kassouf et al.
CANCER (2007)
Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers
Juro Nakanishi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
Histogenesis of sarcomatoid urothelial carcinoma of the urinary bladder: evidence for a common clonal origin with divergent differentiation
M-T Sung et al.
JOURNAL OF PATHOLOGY (2007)
Prospective trial of ifosfamide, paclitaxel, and cisplatin in patients with advanced non-transitional cell carcinoma of the urothelial tract
Matthew D. Galsky et al.
UROLOGY (2007)
Review of the MD Anderson experience in the treatment of bladder sarcoma
Philippe E. Spiess et al.
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS (2007)
Evaluation of the combination of docetaxel/carboplatin in patients with metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group phase II study
Wolfram E. Samlowski et al.
CANCER INVESTIGATION (2007)
When translation meets transformation: the mTOR story
J. Averous et al.
ONCOGENE (2006)
Differences in survival among patients with urachal and nonurachal adenocarcinomas of the bladder
Jonathan L. Wright et al.
CANCER (2006)
Restoring function in exhausted CD8 T cells during chronic viral infection
DL Barber et al.
NATURE (2006)
Long-term-survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Small cell carcinoma of the urinary bladder - The Mayo Clinic experience
NWW Choong et al.
CANCER (2005)
Small cell carcinoma of the bladder: a contemporary clinicopathological study of 51 cases
NA Abrahams et al.
HISTOPATHOLOGY (2005)
Evidence supporting preoperative chemotherapy for small cell carcinoma of the bladder: A retrospective review of the M.D. Anderson cancer experience
AO Siefker-Radtke et al.
JOURNAL OF UROLOGY (2004)
Squamous cell carcinoma of the bladder: pathology, diagnosis and treatment
AA Shokeir
BJU INTERNATIONAL (2004)
Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer
HB Grossman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Clear cell carcinoma of the urinary bladder - A report and comparison of four tumors of mullerian origin and nine of probable urothelial origin with discussion of histogenesis and diagnostic problems
E Oliva et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2002)
Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy amd recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors:: European organization for research and treatment of cancer protocol no. 30924
CN Sternberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
A phase II study of gemcitabine plus cisplatin chemotherapy in advanced bilharzial bladder carcinoma
H. M. Khaled et al.
EUROPEAN JOURNAL OF CANCER (2000)
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy
FA Shepherd et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Gemcitabine and cisplatin versus methotrexate vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large randomized, multinational, multicenter, phase III study
H von der Maase et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
分享论文
